BiotechTube
Home/Idorsia/Martine Clozel
MC

Martine Clozel

Executive VP, Chief Scientific Officer & Head of Research

Idorsia

Therapeutic Areas

CNSCardiovascularImmunologicalOrphan DiseasesInfectious Disease (Vaccines)

Idorsia Pipeline

DrugIndicationPhase
QUVIVIQ (daridorexant)Insomnia DisorderMarketed
TRYVIO/JERAYGO (aprocitentan)Resistant HypertensionMarketed
CenerimodSystemic Lupus Erythematosus (SLE)Phase 3
SelatogrelAcute Myocardial InfarctionPhase 3
LucerastatFabry DiseasePhase 3
ACT-539313Binge Eating DisorderPhase 2b
ACT-1019-0460Undisclosed ImmunologyPhase 1
Vaccine ProgramsBacterial Infections (Prevention)Preclinical/Discovery

Leadership Team at Idorsia

JC
Jean-Paul Clozel
Chairman of the Board & Interim CEO
AG
Arno Groenewoud
Executive VP, Chief Financial Officer
JG
Julien Gander
Chief Legal & Corporate Development Officer
AG
Alberto Gimona
Executive VP, Head of Global Development
View full Idorsia profile